BOLT — Bolt Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1641281 ·
Last close
$3.99
Market Cap
$7.67M
52W High
$5.70
52W Low
$3.75
ADV30
20,057
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 26,000 | — | -7,601,000 | -7,244,000 | 48,027,000 | 11,609,000 | 28,205,000 |
| Dec 2025 | 2,500,000 | — | -5,605,000 | -6,631,000 | 56,748,000 | 11,703,000 | 30,243,000 |
| Sep 2025 | 2,169,000 | — | -7,703,000 | -7,144,000 | 65,053,000 | 17,753,000 | 32,952,000 |
| Jun 2025 | 1,804,000 | — | -9,210,000 | -8,561,000 | 75,499,000 | 9,601,000 | 36,657,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-34,508,000
Investing CF
$37,674,000
Financing CF
$25,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-16.33
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-468,023,000
Inventory
—
Receivables
$973,000
ST Investments
$11,283,000
EBIT TTM
$-30,119,000
Pretax Income TTM
$-29,580,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,499,000
EBITDA
$-29,024,000
Free Cash Flow
$-21,147,376
Enterprise Value
$7,083,052
Total Cash
$22,892,000
Total Debt
$22,308,000
Shares Out
1,921,567
Trailing EPS
$-16.40
Book Value
$10.32
ROE
-88.8%
ROA
-28.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,695,000 | -34,633,000 | -33,376,000 | 56,748,000 | 30,243,000 | — | -39,850,000 |
| Dec 2024 | 7,690,000 | -68,236,000 | -63,118,000 | 99,632,000 | 42,434,000 | — | -61,289,000 |
| Dec 2023 | 7,876,000 | -76,196,000 | -69,197,000 | 159,784,000 | 47,043,000 | — | -69,525,000 |
| Dec 2022 | 5,729,000 | -90,321,000 | -88,098,000 | 227,807,000 | 56,301,000 | — | -76,504,000 |
TTM Snapshot
Revenues TTM
$1,275,000
NetIncome TTM
$-21,195,000
OpCashFlow TTM
$0
Assets (Latest)
$99,632,000
Forward EPS
$-254.96
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| APRE | Aprea Therapeutics, Inc. | $7.68M | $0.62 | — |
| APUS | Apimeds Pharmaceuticals US, Inc. | $7.77M | $5.15 | — |
| INM | InMed Pharmaceuticals Inc. | $7.85M | $1.47 | — |
| MTVA | MetaVia Inc. | $7.33M | $1.42 | — |
| ADIL | ADIAL PHARMACEUTICALS, INC. | $7.31M | $3.34 | — |
News headlines (Yahoo Finance, 1h cache)
Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates
2026-07-28 12:15 · Yahoo
Metastatic HER2-Positive Breast Cancer Market Expected to Surge at a CAGR of 8.3% During the Forecast Period (2026–2036) Due to Advancing Targeted Treatments | DelveInsight
2026-06-01 17:00 · Yahoo
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates
2026-05-12 21:40 · Yahoo
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-12 20:05 · Yahoo
Bolt Metals Corp. Announces Appointment of Chief Financial Officer and Corporate Secretary
2026-04-09 07:00 · Yahoo
Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates
2026-03-12 21:45 · Yahoo
Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot
2026-03-12 20:51 · Yahoo
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
2026-03-12 20:05 · Yahoo
Bolt Biotherapeutics to Participate in Upcoming March Conferences
2026-02-24 13:00 · Yahoo
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates
2025-11-12 22:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.